3rd Quarter - Report

THE NICKLES GROUP, LLC for EMERGENT BIOSOLUTIONS

Firm
Client
Income
$40,000
Expenses
—

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Budget/Appropriations BUD

H.R. 6833, House and Senate Appropriations for 2023.

LobbyistCovered position, as disclosed
DONALD KENT —

Contacted: SENATE

Bills named: H.R. 6833 (117th)

Health Issues HCR

Opioid and heroin addiction legislation, naloxone access and awareness and opioid prescribing guidelines. S. 3799, PREVENT Pandemics Act.

LobbyistCovered position, as disclosed
DONALD KENT —

Contacted: SENATE

Bills named: S. 3799 (117th)

Defense DEF

NDAA for FY 2023 - provisions related to biological and chemical defense and access to naloxone.

LobbyistCovered position, as disclosed
DONALD KENT —

Contacted: SENATE

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.